Adicet Bio, Inc. ACET
Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026
Adicet Bio, Inc. (ACET) is a healthcare company listed in the US with a market value of about $26M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -51%.
About Adicet Bio
Adicet Bio is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. It was profitable in 0 of the last 9 years in our data. Its share count rose by 168% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — |
| Net income | -$117M | -$117M | -$143M | -$70M | -$62M | -$37M | -$28M | -$9M | -$34M |
| Free cash flow | -$97M | -$93M | -$98M | -$62M | -$64M | -$43M | -$29M | -$19M | -$11M |
| EPS (diluted) | $-16.95 | $-21.33 | $-52.96 | $-27.20 | $-32.00 | $-80.16 | $-210.40 | $-76.48 | $-2160.74 |
| Net margin | — | — | — | — | — | — | — | — | — |
| ROIC | -70.6% | -62.6% | -79.6% | -23.2% | -18.9% | -27.7% | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $29.00, 943% above the current price; targets range from $18.00 to $55.00; the consensus rating is “Strong buy”; expected EPS is $-7.33 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Adicet Bio pay a dividend?
Not currently.
Is Adicet Bio a good stock to buy?
We do not give buy or sell advice. Adicet Bio scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.